Ausiello Dennis A 4

Accession 0001735276-25-000079

CIK 0001178670other

View on SEC.gov Company Profile

Filed

Aug 14, 8:00 PM ET

Accepted

Aug 15, 4:05 PM ET

Size

45.8 KB

Accession

0001735276-25-000079

Insider Transaction Report

Form 4

Period: 2025-08-14

ALNYLAM PHARMACEUTICALS, INC.ALNY

Ausiello Dennis A

Director

Transactions

Exercise/Conversion
Common Stock
2025-08-14$148.77/sh+4,581$681,515→ 19,645 total
Exercise/Conversion
Common Stock
2025-08-14$189.87/sh+3,454$655,811→ 32,359 total
Sale
Common Stock
2025-08-14$430.81/sh−1,985$855,158→ 30,374 total
Sale
Common Stock
2025-08-14$440.54/sh−1,238$545,389→ 2,757 total
Sale
Common Stock
2025-08-14$442.66/sh−641$283,745→ 911 total
Exercise/Conversion
Stock Option (right to buy)
2025-08-14−3,454→ 0 total
Exercise: $189.87From: 2024-05-18Exp: 2033-05-18→ Common Stock (3,454 underlying)
Sale
Common Stock
2025-08-14$432.94/sh−1,938$839,038→ 28,436 total
Exercise/Conversion
Stock Option (right to buy)
2025-08-14−5,153→ 0 total
Exercise: $128.31From: 2023-05-18Exp: 2032-05-17→ Common Stock (5,153 underlying)
Exercise/Conversion
Common Stock
2025-08-14$171.95/sh+4,032$693,302→ 28,905 total
Sale
Common Stock
2025-08-14$438.34/sh−2,086$914,377→ 9,297 total
Exercise/Conversion
Stock Option (right to buy)
2025-08-14−4,032→ 0 total
Exercise: $171.95From: 2022-07-15Exp: 2031-07-14→ Common Stock (4,032 underlying)
Sale
Common Stock
2025-08-14$434.50/sh−2,098$911,581→ 26,338 total
Sale
Common Stock
2025-08-14$436.00/sh−5,358$2,336,088→ 13,305 total
Exercise/Conversion
Common Stock
2025-08-14$128.31/sh+5,153$661,181→ 15,064 total
Exercise/Conversion
Common Stock
2025-08-14$151.22/sh+5,228$790,578→ 24,873 total
Sale
Common Stock
2025-08-14$437.56/sh−1,922$840,990→ 11,383 total
Exercise/Conversion
Stock Option (right to buy)
2025-08-14−4,581→ 0 total
Exercise: $148.77From: 2021-07-01Exp: 2030-07-01→ Common Stock (4,581 underlying)
Sale
Common Stock
2025-08-14$439.27/sh−5,302$2,329,010→ 3,995 total
Sale
Common Stock
2025-08-14$441.88/sh−1,205$532,465→ 1,552 total
Exercise/Conversion
Stock Option (right to buy)
2025-08-14−9,000→ 0 total
Exercise: $72.01From: 2020-07-01Exp: 2029-06-30→ Common Stock (9,000 underlying)
Exercise/Conversion
Common Stock
2025-08-14$72.01/sh+9,000$648,090→ 9,911 total
Sale
Common Stock
2025-08-14$435.40/sh−7,675$3,341,695→ 18,663 total
Exercise/Conversion
Stock Option (right to buy)
2025-08-14−5,228→ 0 total
Exercise: $151.22From: 2025-05-16Exp: 2034-05-16→ Common Stock (5,228 underlying)

Holdings

Common Stock
(indirect: By Trust)
3,500

Footnotes (19)

[F1]All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 15, 2025.
[F10]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $440.24 to $440.93 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F11]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $441.41 to $442.11 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F12]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $442.44 to $443.10 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F13]The shares of ALNY common stock are held in a trust, of which the reporting person's spouse is the trustee.
[F14]The stock option was fully vested as of July 1, 2020.
[F15]The stock option was fully vested as of May 18, 2023.
[F16]The stock option was fully vested as of July 1, 2021.
[F17]The stock option was fully vested as of May 16, 2025.
[F18]The stock option was fully vested as of July 15, 2022.
[F19]The stock option was fully vested as of May 18, 2024.
[F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $430.39 to $431.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $432.10 to $433.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $433.59 to $434.56. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F5]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $434.69 to $435.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F6]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $435.79 to $436.35 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F7]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $436.84 to $437.83 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F8]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $437.85 to $438.71 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F9]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $438.91 to $439.89 The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

ALNYLAM PHARMACEUTICALS, INC.

CIK 0001178670

→

Entity typeother

Related Parties

filerCIK 0001381994

Filing Metadata

Form type: 4
Filed: Aug 14, 8:00 PM ET
Accepted: Aug 15, 4:05 PM ET
Size: 45.8 KB

View on SEC.gov